Jump to content
RemedySpot.com

Dynavax Phase 1B safety and immunogenicity study shows tolerance and safety of doses of DV-601

Rate this topic


Recommended Posts

Posted

http://www.therapeuticsdaily.com/news/article.cfm?contentValue=

1978791 & contentType=sentryarticle & channelID=26

Dynavax Phase 1B safety and immunogenicity study shows tolerance and safety of

doses of DV-601

EquityBites - Dec. 24, 2010

Clinical-stage biopharmaceutical company Dynavax Technologies Corporation

(Nasdaq:DVAX) on Thursday reported safety and immunogenicity data from its Phase

1b clinical trial of DV-601, its proprietary hepatitis B therapeutic vaccine.

The dose escalation study assessed safety and the immunologic and virologic

responses in 14 subjects with chronic hepatitis B infection.

The company said that the Phase 1b data showed that all doses were generally

safe and well tolerated. Also, individual immunologic and virologic responses

were observed across cohorts at all dose levels.

No conclusions regarding the potential clinical impact of the therapy could be

reached in this small study.

The company's candidate vaccine, DV-601, is designed to induce an immune

response against HBV-infected cells and if proven to be safe and effective, may

offer an alternative therapeutic option for patients chronically infected with

HBV.

Posted

http://www.therapeuticsdaily.com/news/article.cfm?contentValue=

1978791 & contentType=sentryarticle & channelID=26

Dynavax Phase 1B safety and immunogenicity study shows tolerance and safety of

doses of DV-601

EquityBites - Dec. 24, 2010

Clinical-stage biopharmaceutical company Dynavax Technologies Corporation

(Nasdaq:DVAX) on Thursday reported safety and immunogenicity data from its Phase

1b clinical trial of DV-601, its proprietary hepatitis B therapeutic vaccine.

The dose escalation study assessed safety and the immunologic and virologic

responses in 14 subjects with chronic hepatitis B infection.

The company said that the Phase 1b data showed that all doses were generally

safe and well tolerated. Also, individual immunologic and virologic responses

were observed across cohorts at all dose levels.

No conclusions regarding the potential clinical impact of the therapy could be

reached in this small study.

The company's candidate vaccine, DV-601, is designed to induce an immune

response against HBV-infected cells and if proven to be safe and effective, may

offer an alternative therapeutic option for patients chronically infected with

HBV.

Join the conversation

You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Loading...
×
×
  • Create New...